Table 5.
Recommendations of intravesical therapy for high risk patientsa
| Guideline ID | High risk | |||||||
|---|---|---|---|---|---|---|---|---|
| Induction | Maintenance | |||||||
| Be recommended | Be recommended | Course of treatment | ||||||
| Chemotherapy | BCG | Chemotherapy | BCG | Chemotherapy | BCG | |||
| SOR/LOE | SOR/LOE | SOR/LOE | SOR/LOE | Course | SOR/LOE | Course | SOR/LOE | |
| ESMO, 2014 [8] | −/− | −/− | −/− | −/− | – | −/− | – | −/− |
| NICE, 2015 [9]b | −/− | A/high-very low | −/− | A/high-very low | – | −/− | – | −/− |
| CUA, 2015 [10] | −/− | A/− | −/− | B/− | – | −/− | Full dose, 3 years | B/− |
| AUA/SUO, 2016 [3] | −/− | Strong/B | −/− | Moderate/B | – | −/− | 3 years | Moderate/B |
| JUA, 2016 [11] | −/− | −/− | −/− | −/− | – | −/− | – | −/− |
| EAU, 2018 [12] | −/− | −/− | −/− | Strong/1a-1b | – | −/− |
Full dose, 1–3 years Three-weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months |
Strong/1a-1b |
| ICUD/SIU, 2018 [13] | B/2 | A/1 | C/2 | B/2 | 1 year | C/2 | 3 years | B/2 |
| CRHA/CPAM, 2018 [14] | A/1a | A/1a | A/1a | A/1a | Monthly for 6–10 months | A/1a | Full dose, 3 years | B/1b |
| NCCN, 2019 [15]c | B/2A | A/1 | B/2A | A/2A | – | B/2A |
3 years Three-weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months |
B/2A |
a The SOR and LOE are presented as “SOR/LOE”. “-” indicates that the recommendation or evidence was not presented
b To simplify the table, we used “A” and “B” instead of “should/should not/offer/do not offer/refer/advise” or “consider” for presenting SOR
c To simplify the table, we used “A” and “B”, “C” instead of “preferred intervention”, “other recommended intervention”, or “useful in certain circumstances” for presenting SOR